This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.
ABTNegative Net Change BSXNegative Net Change ISRGNegative Net Change
medical medical-devices
EYE Stock: Valuation, Price Target, and Key Upside Drivers
by Moumi Mondal
National Vision trades at 0.6X forward sales after a steep 2026 decline. Can steady execution, margin gains and sales growth support its $17 price target?
WMTPositive Net Change COSTPositive Net Change EYEPositive Net Change
medical medical-devices
Is the Options Market Predicting a Spike in Prestige Consumer Stock?
by Zacks Equity Research
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
PBHPositive Net Change
medical-devices
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
by Zacks Equity Research
Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.
WSTNegative Net Change GMEDNegative Net Change NTRANegative Net Change BDSXPositive Net Change
medical medical-devices
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
by Zacks Equity Research
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change PACBNegative Net Change
medical medical-devices
Block (XYZ) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
XYZPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AUTLNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
by Zacks Equity Research
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
ABTNegative Net Change ALGNNegative Net Change IARTPositive Net Change GMEDNegative Net Change
medical medical-devices
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
by Zacks Equity Research
CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.
CNMDPositive Net Change GMEDNegative Net Change PACBNegative Net Change BDSXPositive Net Change
medical medical-devices
HealthEquity Stock Gains as Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.
ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change HQYNegative Net Change
earnings medical medical-devices